Pharmaceutical Contract Development And Manufacturing Organization (CMO) Market Analysis Report 2026: $90.75+ Bn Opportunities, Trends, Competitive Landscape, Strategies, And Forecasts, 2020-2035

(MENAFN- GlobeNewsWire - Nasdaq) The CDMO market is poised for growth due to rising R&D spending, increased demand for generics and biologics, patent expirations, technological integration, and strategic partnerships. Opportunities lie in expanding service portfolios, regional manufacturing, and optimizing supply chains for cost efficiency.

Dublin, April 30, 2026 (GLOBE NEWSWIRE) -- The "Pharmaceutical Contract Development and Manufacturing Organization (CMO) Market Report 2026" has been added to ResearchAndMarkets's offering.

The comprehensive market report covers various aspects including statistics, regional shares, competitor data, and trends necessary for thriving in this sector. The pharmaceutical CDMO services span contract manufacturing and research services, serving large, generic, and small to medium pharmaceutical companies. The market value includes revenue from products and services, emphasizing only sales conducted between entities or directly to consumers. This industry is pivotal in ensuring efficient drug development and manufacturing processes globally.

The pharmaceutical contract development and manufacturing organization (CMO) market has experienced significant growth, with projections indicating an increase from $54.73 billion in 2025 to $60.7 billion in 2026, growing at a compound annual growth rate (CAGR) of 10.9%. This trend is fueled by rising R&D expenditures, the prevalence of chronic diseases, generic drug demand, technological advancements, and a focus on research. Looking ahead, the market is set to reach $90.76 billion by 2030 at a CAGR of 10.6%, driven by personalized medicine adoption, biologics demand, emerging market expansions, digital integration in drug development, and increased strategic partnerships.

The growth trajectory also benefits from the increasing rate of patent expirations, which propels the demand for CDMO services. For instance, as per DrugTimes, in February 2024, over 25 pharmaceutical products will lose patent protection, potentially decreasing revenue by over $236.4 billion by 2037. This scenario underscores the pivotal role of CDMOs in enabling generic drug market entry post-patent expiry.

Key players in the CDMO market are expanding their portfolios to align with evolving needs. An example is ASM Research Chemicals, which launched the DevPack service in May 2023. DevPack, optimized across multiple partners, offers a standardized dataset for API manufacturing, aiding analytical development, regulatory submissions, and process development. Such innovations are vital for companies targeting accelerated API development.

In a strategic acquisition move, Ajinomoto Group acquired Forge Biologics Inc. in December 2023. This acquisition aims to bolster Ajinomoto's gene therapy CDMO capabilities and enhance its biopharmaceutical manufacturing presence globally. Forge Biologics, a US-based CDMO, specializes in AAV-based gene therapy solutions.

Prominent companies in this landscape include Lonza Group, Catalent Inc, WuXi AppTec Inc., Recipharm AB, among others. Geographically, North America dominated the market in 2025, while the Middle East is expected to be the fastest-growing region during the forecast period. Market challenges include tariffs that have increased costs, particularly in API manufacturing and formulation development, prompting local sourcing and regional manufacturing investments.

Report Scope

Markets Covered:

• By Type: Contract Manufacturing Services; Contract Research Services
• By Research Phase: Preclinical; Phase I; Phase II; Phase III; Phase IV
• By End User: Large Pharmaceuticals; Generics; Small to Medium Enterprises

Subsegments:

• Contract Manufacturing: API Manufacturing, Formulation Development, Finished Dosage Form Manufacturing, Packaging, Supply Chain Management
• Contract Research: Preclinical Research, Clinical Trials, Regulatory Affairs, Biostatistics, Analytical Services

Companies Mentioned: Lonza Group, Catalent Inc., WuXi AppTec Inc., Recipharm AB, Almac Group, Baxter International Inc., and more.

Countries Covered: Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Regions: Asia-Pacific, Southeast Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Key Attributes:

Report Attribute	Details
No. of Pages	250
Forecast Period	2026 - 2030
Estimated Market Value (USD) in 2026	$60.7 Billion
Forecasted Market Value (USD) by 2030	$90.76 Billion
Compound Annual Growth Rate	10.6%
Regions Covered	Global

Major Trends

• Outsourcing of Drug Development and Manufacturing
• Expansion of Cdmo Service Portfolios
• Regulatory Compliance and Quality Assurance Focus
• Strategic Partnerships Between Pharma Companies and Cdmos
• Adoption of Advanced Analytical and Testing Services

Companies Featured

• Lonza Group
• Catalent Inc
• WuXi AppTec Inc.
• Recipharm AB
• Almac Group
• Aenova Group
• Baxter International Inc
• SGS Life Science Services SA
• Jubilant Pharmova Ltd
• Dishman Pharmaceuticals
• Kemwell Pvt. Ltd.
• Nipro Corp.
• CMIC Group
• Sawai Pharmaceutical Co. Ltd
• IDT Australia Limited
• Aurigene Pharmaceutical Services Limited
• Vetter Pharma International GMBH
• Consort Medical PLC
• Siegfried Holding AG
• Evonik Industries
• NextPharma
• Royal DSM N.V
• HAUPT Pharma AG
• Famar
• OTC-PharmNEUCA
• Farmacol
• Polska Grupa Farmaceutyczna
• Polpharma
• TZMO
• Eurofarma Laboratorios S.A.
• Ache Laboratorios Farmaceuticos S.A.
• Blanver Farmoquimica e Farmaceutica S.A.
• Prati-Donaduzzi
• Uniao Quimica Farmaceutica Nacional S.A
• Laboratorios Richmond S.A.C.I.F.
• Bago S.A.
• Elea Laboratories S.A.C.I. y F.
• Gador S.A.
• LIFEPharma
• Neopharm
• Gulf Pharmaceutical Industries JULPHA
• NewBridge Pharmaceuticals Limited
• Aspen Pharmacare Holdings Limited
• Adcock Ingram Holdings Limited
• Pharma-Q (Pty) Ltd
• Vital Health Foods
• EIPICO (Egyptian International Pharmaceutical Industries Company)
• Pharco Pharmaceuticals

For more information about this report visit

About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Attachment

• Pharmaceutical Contract Development and Manufacturing Organization (CMO) Market

CONTACT: CONTACT: Laura Wood,Senior Press Manager... For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

MENAFN30042026004107003653ID1111052905